CryoLife, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. It offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, pulmonary, and general surgical applications; On-X prosthetic aortic and mitral heart valve, and On-X ascending aortic prosthesis; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita OPEN PLUS and E-vita OPEN NEO, a hybrid stent graft system. The company also provides E-xtra DESIGN ENGINEERING products for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-nya, a thoracic stent graft system for the minimally invasive repair of lesions of the descending aorta; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, an abdominal aortic aneurysms stent graft system. In addition, it offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; and cardiac laser therapy products, such as SolarGen 2100s Console and SoloGrip III disposable handpieces. Further, the company sells CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as offers pyrolytic carbon coating services to other medical device manufacturers. The company serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. CryoLife, Inc. was founded in 1984 and is headquartered in Kennesaw, Georgia.
IPO Year:
Exchange: NYSE
Website: cryolife.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/7/2022 | $29.00 → $25.00 | Equal-Weight | Morgan Stanley |
| 7/30/2021 | $31.00 → $32.00 | Equal-Weight | Morgan Stanley |
| 7/30/2021 | $38.00 → $39.00 | Buy | Needham |
| 7/15/2021 | $31.00 | Equal-Weight | Morgan Stanley |
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Morgan Stanley reiterated coverage of Cryolife with a rating of Equal-Weight and set a new price target of $25.00 from $29.00 previously
Morgan Stanley reiterated coverage of Cryolife with a rating of Equal-Weight and set a new price target of $32.00 from $31.00 previously
Needham reiterated coverage of Cryolife with a rating of Buy and set a new price target of $39.00 from $38.00 previously
Morgan Stanley initiated coverage of Cryolife with a rating of Equal-Weight and set a new price target of $31.00
Needham reiterated coverage of Cryolife with a rating of Buy and set a new price target of $38.00 from $33.00 previously
Needham reiterated coverage of Cryolife with a rating of Buy and set a new price target of $33.00 from $28.00 previously
8-K - ARTIVION, INC. (0000784199) (Filer)
8-A12B/A - CRYOLIFE INC (0000784199) (Filer)
8-K - CRYOLIFE INC (0000784199) (Filer)
8-K - CRYOLIFE INC (0000784199) (Filer)
10-Q - CRYOLIFE INC (0000784199) (Filer)
8-K - CRYOLIFE INC (0000784199) (Filer)
DEFA14A - CRYOLIFE INC (0000784199) (Filer)
DEF 14A - CRYOLIFE INC (0000784199) (Filer)
PRE 14A - CRYOLIFE INC (0000784199) (Filer)
8-K - CRYOLIFE INC (0000784199) (Filer)
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - CRYOLIFE INC (0000784199) (Issuer)
4 - CRYOLIFE INC (0000784199) (Issuer)
4 - CRYOLIFE INC (0000784199) (Issuer)
4 - CRYOLIFE INC (0000784199) (Issuer)
3 - CRYOLIFE INC (0000784199) (Issuer)
4 - CRYOLIFE INC (0000784199) (Issuer)
4 - CRYOLIFE INC (0000784199) (Issuer)
4 - CRYOLIFE INC (0000784199) (Issuer)
4 - CRYOLIFE INC (0000784199) (Issuer)
4 - CRYOLIFE INC (0000784199) (Issuer)
Fastest customizable press release news feed in the world
ATLANTA, Jan. 18, 2022 /PRNewswire/ -- CryoLife, Inc. (NYSE:CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it was renaming and rebranding itself to Artivion, Inc., effective immediately. Derived from the words "aorta", "innovation", and "vision", the company's new name and brand reflect its evolution to focus on providing innovative technologies to surgeons who treat patients with aortic disease. In conjunction with these changes, effective January 24, 2022, the company will also change its ticker symbol on the New York Stock Exchange to "AORT" from "CRY."
ATLANTA, Nov. 9, 2021 /PRNewswire/ -- CryoLife, Inc. (NYSE:CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that members of management will host one-on-one meetings at the upcoming Canaccord Genuity MedTech, Diagnostics, and Digital Health & Services Forum on Thursday, November 18, 2021. Due to the format of this event no webcast will be available. For more information on the company, please visit CryoLife's website, www.cryolife.com, on the Investor Relations page. About CryoLife, Inc.Headquartered in suburban Atlanta, Georgia,
ATLANTA, Nov. 4, 2021 /PRNewswire/ -- Third Quarter and Recent Business Highlights: Achieved total revenues of $72.2 million in the third quarter 2021 versus $65.1 million in the third quarter of 2020, an increase of 11% on a GAAP basis and 9% on a non-GAAP proforma constant currency basis Net income was $10.6 million, or $0.26 per share, in the third quarter of 2021 Non-GAAP net loss was ($1.2) million, or ($0.03) per share, in the third quarter of 2021CryoLife, Inc. (NYSE:CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today its fina
ATLANTA, Oct. 20, 2021 /PRNewswire/ -- CryoLife, Inc. (NYSE:CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that third quarter 2021 financial results will be released on Thursday, November 4, 2021 after the market closes. On that day, the Company will hold a teleconference call and live webcast at 4:30 p.m. ET to discuss the results, followed by a question and answer session hosted by Pat Mackin, Chairman, President and Chief Executive Officer of CryoLife, Inc. To participate in the conference call dial 862-298-0702 a few minutes
ATLANTA, Sept. 22, 2021 /PRNewswire/ -- CryoLife, Inc. (NYSE:CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today the appointment of Anthony "Tony" Semedo to its Board of Directors effective October 1, 2021. "We are thrilled to welcome Tony, a leader in the aortic space, to our board of directors," commented Pat Mackin, Chairman, President, and Chief Executive Officer. "Tony's demonstrated ability to lead, grow, and integrate diversified global divisions in the medical device space as well as his experience managing robust R&D, quali
ATLANTA, Aug. 31, 2021 /PRNewswire/ -- CryoLife, Inc. (NYSE:CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it will participate in the upcoming Morgan Stanley 19th Annual Global Healthcare Conference on Tuesday, September 14, 2021. The Company's virtual fireside chat is scheduled to begin at 12:30 p.m. ET. A live webcast of the virtual fireside chat will be accessible through CryoLife's website, www.cryolife.com, on the Investor Relations page. An archived copy of the webcast will be available for 90 days on the same websit
ATLANTA, Aug. 2, 2021 /PRNewswire/ -- CryoLife, Inc. (NYSE:CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it will participate in two upcoming virtual investor conferences. CryoLife's management team will present at the upcoming Canaccord Genuity 41st Annual Growth Conference on Wednesday, August 11, 2021. The Company's presentation is scheduled to begin at 9:30 a.m. ET. A live webcast of the presentation will be accessible through CryoLife's website, www.cryolife.com, on the Investor Relations page. An archived copy of the
ATLANTA, July 29, 2021 /PRNewswire/ -- Second Quarter and Recent Business Highlights: Achieved total revenues of $76.1 million in the second quarter 2021 versus $53.8 million in the second quarter of 2020, an increase of 42% on a GAAP basis and 35% on a non-GAAP proforma constant currency basis Net loss was ($2.2) million, or ($0.06) per share, in the second quarter of 2021 Non-GAAP net income was $4.8 million, or $0.12 per share, in the second quarter of 2021 CryoLife, Inc. (NYSE:CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today i
ATLANTA, July 15, 2021 /PRNewswire/ -- CryoLife, Inc. (NYSE:CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that second quarter 2021 financial results will be released on Thursday, July 29, 2021 after the market closes. On that day, the Company will hold a teleconference call and live webcast at 4:30 p.m. ET to discuss the results, followed by a question and answer session hosted by Pat Mackin, Chairman, President and Chief Executive Officer of CryoLife, Inc. To listen to the live teleconference, please dial 201-689-8261 a few m
ATLANTA, May 18, 2021 /PRNewswire/ -- CryoLife, Inc. (NYSE:CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it will participate in the upcoming UBS Global Healthcare Virtual Conference on Tuesday, May 25, 2021. The Company's virtual fireside chat is scheduled to begin at 11:00 a.m. ET. A live webcast of the virtual fireside chat will be accessible through CryoLife's website, www.cryolife.com, on the Investor Relations page. An archived copy of the webcast will be available for 90 days on the same website. About CryoLife,
Live Leadership Updates
ATLANTA, Sept. 22, 2021 /PRNewswire/ -- CryoLife, Inc. (NYSE:CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today the appointment of Anthony "Tony" Semedo to its Board of Directors effective October 1, 2021. "We are thrilled to welcome Tony, a leader in the aortic space, to our board of directors," commented Pat Mackin, Chairman, President, and Chief Executive Officer. "Tony's demonstrated ability to lead, grow, and integrate diversified global divisions in the medical device space as well as his experience managing robust R&D, quali
Live finance-specific insights
ATLANTA, Nov. 4, 2021 /PRNewswire/ -- Third Quarter and Recent Business Highlights: Achieved total revenues of $72.2 million in the third quarter 2021 versus $65.1 million in the third quarter of 2020, an increase of 11% on a GAAP basis and 9% on a non-GAAP proforma constant currency basis Net income was $10.6 million, or $0.26 per share, in the third quarter of 2021 Non-GAAP net loss was ($1.2) million, or ($0.03) per share, in the third quarter of 2021CryoLife, Inc. (NYSE:CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today its fina
ATLANTA, Oct. 20, 2021 /PRNewswire/ -- CryoLife, Inc. (NYSE:CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that third quarter 2021 financial results will be released on Thursday, November 4, 2021 after the market closes. On that day, the Company will hold a teleconference call and live webcast at 4:30 p.m. ET to discuss the results, followed by a question and answer session hosted by Pat Mackin, Chairman, President and Chief Executive Officer of CryoLife, Inc. To participate in the conference call dial 862-298-0702 a few minutes
ATLANTA, July 29, 2021 /PRNewswire/ -- Second Quarter and Recent Business Highlights: Achieved total revenues of $76.1 million in the second quarter 2021 versus $53.8 million in the second quarter of 2020, an increase of 42% on a GAAP basis and 35% on a non-GAAP proforma constant currency basis Net loss was ($2.2) million, or ($0.06) per share, in the second quarter of 2021 Non-GAAP net income was $4.8 million, or $0.12 per share, in the second quarter of 2021 CryoLife, Inc. (NYSE:CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today i
This live feed shows all institutional transactions in real time.
SC 13G/A - CRYOLIFE INC (0000784199) (Subject)
SC 13G - CRYOLIFE INC (0000784199) (Subject)
SC 13G/A - CRYOLIFE INC (0000784199) (Subject)